Why not join CURE today? You already belong!

Good for bioscience in Connecticut. Good for you.

The CURE Calendar

BioHaven Presents: Growing Arvinas – Technology, Investment and Business Development: Three Perspectives @ Anlyan Center at Yale
May 26 @ 4:00 pm – 6:00 pm


Arvinas ( is a pharmaceutical company located in New Haven, CT, founded on platform technology developed by Craig Crews at Yale University and focused on developing novel therapeutics to treat a variety of cancer indications. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation, thus eliminating them from the body.  This strategy of degradation versus protein inhibition holds several advantages, including the potential to target proteins that are not currently druggable using a small molecule approach. In addition to developing its pipeline of wholly-owned molecules, Arvinas is engaged in collaborations with Merck and Genentech. In 2015 Arvinas was selected by FierceBiotech as one of its “Fierce 15” biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.


Susan Froshauer, Ph.D. Dr. Froshauer is President and CEO of CURE and President of CURE Innovations, LLC. She is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Her passion and commitment is helping bioscience entrepreneurs build successful companies.



 Tim Shannon:

Timothy Shannon, MD

Timothy Shannon, MD is the Chairman of the Board of Arvinas and a Venture Partner at Canaan Partners. He also serves on the boards of Aldea Pharmaceuticals,Civitas TherapeuticsCytomX Therapeutics and Novira Therapeutics, Canaan portfolio companies.

Dr. Shannon previously was president and chief executive officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer.  He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group including senior vice president of global medical development.  Prior to his career in industry, Dr. Shannon was assistant professor of the pulmonary and critical care division at Yale University School of Medicine.

Dr. Shannon received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.

Manny Litchman:

Manny Litchman, MD

Manny is the President and CEO of Arvinas Inc.  Previously, he was Senior Vice President and Global Program Head at Novartis Pharmaceuticals for the CTL019 project – a collaboration with the University of Pennsylvania (Penn) involving personalized cell and gene therapy. Manny started his pharmaceutical career in Oncology Clinical Research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he held positions of increasing responsibility in Oncology Development. From 2000 – 2001 he was Senior Equity Analyst at Ursus Capital, a biotechnology hedge fund. He then returned to Novartis, where he was Head of Oncology Business Development & Licensing until execution of the Penn deal in 2012. Manny obtained his BA in German Literature from Princeton University and his MD from Yale University School of Medicine. He completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital / Weill Cornell Medical Center.

Craig Crews:

Craig M. Crews, Ph.DCraig Crews is the Founder and Chief Scientific Advisor of Arvinas as well as the L.B. Cullman Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University.

Dr. Crews’ research focuses on the design/syntheses/evaluation of small molecule regulators of intracellular protein levels and their development as novel therapeutics.  YU101, a novel proteasome inhibitor from his lab served as the lead asset in Proteolix, Inc. (purchased by Onyx in 2009;acquired by Amgen 2013) and became carfilzomib/Kyprolis™, which received FDA approval for relapsed/refractory multiple myeloma in 2012.

Sean Cassidy:

Sean Cassidy, CPASean Cassidy is the Chief Financial Officer of Arvinas.  He has over 20 years experience in the life sciences industry, including: Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents; and Deloitte, one of the big four public accounting firms serving a broad base of clients in the health care space.

Sean is also the Treasurer of the Friends of Yale New Haven Children’s Hospital, a non-profit organization that help improve the health and well-being of pediatric patients and their families.

Mr. Cassidy holds an MBA and BS from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.


2016 BIO International Convention
Jun 6 – Jun 9 all-day

The global event for biotechnology returns to the birthplace of biotech, San Francisco, California. The region continues to grow and advance biomedical innovation while continuing to offer programs and services to support to bring new medical advances to patients. Imagine all of the powerful partnerships when these powerful communities of innovation come together – mark your calendar today!

Visit BIO website for more information:

Investor & Entrepreneur Network Event
Jun 9 @ 8:30 pm – 11:30 pm

Join the movers and shakers of the investment and entrepreneurial community for CVG’s monthly Investor & Entrepreneur Network Event!

Happiness Program
Jun 9 @ 11:30 pm – Jun 12 @ 10:00 pm

Dear All – Please find the details on the next Happiness Program below. I would highly recommend you to sign up if you have not repeated Happiness program in the last 6mths.

Sudarshan Kriya, a powerful breathing technique and other ancient practices
Valuable skills for managing negative emotions and challenging situations, for improving focus and productivity at work and strengthening relationships
Practical wisdom and processes to discover what in your life is working for you and what is not working for you
Low-impact yoga for improved health and increased flexibility


“The secret lies in our own breath. Through breathing exercises, certain breathing techniques and some practice of meditation, we can rekindle positive vibrations within and around us.” — Sri Sri Ravi Shankar, Founder of the Art of Living Foundation

Reduced stress
Greater sense of joy, happiness and enthusiasm
Experience more confidence
Development of interpersonal skills


“The Art of Living course is the most precious gift I have ever received. The knowledge spoken and the practices taught were shared with so much love. I have happiness, strength and peace. The world has been waiting for this course. ”
— Daniel Mendez, Writer, Houston, Texas

“The Sudarshan Kriya has dissipated alot of the worries and anxieties I had in my life. Now I am able to deal with every day challenges with a feeling of inner strength. ” — John Chu, Realtor Miami, Florida

“The Art of Living course practices have changed my life. Negative emotions do not have the same grip on me and they go away faster. I really think my health has improved also. I am strongly recommending the course to all my friends, family, and patients.” — Jyotsna Sahni, Doctor Detroit, MI
Read more
Live with Joy, Purpose and Confidence

Within you lie vast, untapped possibilities waiting to be discovered. Through The Happiness Program you’ll learn practical and powerful techniques that will enable you to gain a greater vision of who you are and benefit you for the rest of your life. You will find yourself enabled to create a more joyous, purposeful life, and gain the confidence to stretch and grow beyond limiting beliefs

In today’s demanding, distracting world your mind can be stuck in the past or in the future. But happiness is here in the present moment. It cannot be experienced when you’re regretting yesterday or worried about tomorrow. During The Happiness Program you’ll reconnect with your unlimited power and freedom — not as a concept, but as a direct experience.

Sudarshan Kriya®
The centerpiece of The Happiness Program is Sudarshan Kriya, a powerful breathing technique that uses specific, natural rhythms to not only release stress at the deepest level, but also balance and integrate mind, body and heart.

Your course will also include:

· Stretching and low-impact yoga for health, circulation, and physical well-being.

· Guided meditation and breathing techniques that increase energy and deeply relax the body and mind.

· Skills for handling negative emotions and situations.

· Practical wisdom for improving focus at work and harmony in relationships.

· Guided interactive processes

Health Benefits

Research has demonstrated that Sudarshan Kriya and the related practices you’ll learn can bring about the following benefits:

· Can significantly reduce (the stress hormone) cortisol

· Are effective in relieving depression and anxiety

· Help to restore normal sleep patterns, and

· Increase prolactin (the hormone associated with well-being).

By the end of the course you’ll be equipped with specific techniques that you can practice every day. The value of these practices is both cumulative and immediate; you can look forward to continued and increasing benefits. You’ll also have access to ongoing follow-up programs which take place all over the world.

Please note that it’s required to attend all sessions of the course.

If you’re a licensed professional in a health-related field you may be able to earn continuing education units for attending The Happiness Program. Please contact Art of Living Foundation’s CEU Administrator for additional information on this at

CURE Annual Meeting @ CURE Innovation Commons
Jun 14 @ 4:00 pm – 5:00 pm


Susan Froshauer, Ph.D.





John-BurkhardtJohn Burkhardt is Vice President, Global Drug Safety Research and Development, Groton Labs Site Director, Pfizer. Prior to rejoining Pfizer, John led AbbVie Preclinical Safety from 2008-2015. His knowledge base covers early drug discovery, late stage development, regulatory review and approval of both small and large molecules. John knows Pfizer well as he worked in Pfizer Drug Safety for 15 years prior to heading Preclinical Safety at AbbVie. While in Pfizer Drug Safety (Groton, Sandwich, and Amboise, France) John helped develop and implement many of the early discovery support plat-forms, like target safety assessment and discovery pathology support, that we still utilize in Pfizer today.

John earned his Doctor of Philosophy and Residency in Anatomic Pathology at Purdue University School of Veterinary Medicine and Animal Disease Diagnostic Laboratory, West Lafayette, Indiana, May, 1992. He received his Bachelor of Science degree and his Doctor of Veterinary Medicine at Purdue University School of Agriculture, West Lafayette, Indiana, in May 1985 and 1988, respectively.

Erin Duffy, Ph.D. is the chief scientific officer of Melinta Therapeutics, responsible for translating the company’s Nobel Prize-winning crystallography ribosome modeling into the discovery and early-stage development of novel antibiotic candidates. She joined the company in 2002 and has become one of the world’s leading experts on the structure and function of the bacterial ribosome and the interaction of antibiotics with their ribosomal targets.
Dr. Duffy has led Melinta’s ESKAPE Pathogen Program from its infancy and has been instrumental in advancing the platform while also contributing to the development programs for other medication candidates. The ESKAPE Pathogen Program is Melinta’s most advanced preclinical program, focused on using a discrete, novel binding site within the bacterial ribosome to design and develop completely new classes of antibiotics to treat some of the most deadly and difficult-to-treat, multi-drug resistant Gram-positive and Gram-negative infections.

Prior to joining Melinta, Dr. Duffy served as the associate director of innovative discovery technologies at Achillion Pharmaceuticals, Inc. Dr. Duffy began her scientific career as a computational chemist with Pfizer Global Research and Development in Groton, Connecticut.

Dr. Duffy was trained at Yale University, where she received her Ph.D. in 1994 in physical-organic chemistry and was a Howard Hughes postdoctoral fellow. She holds a Bachelor of Science degree in chemistry from Wheeling Jesuit University.

Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was the Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011. Before that, he served as an executive-in- residence at Canaan Partners. Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly held pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. He currently serves as a Board member of Cheetah Medical, Inc. (Chairman), Histogenics Corp., Collagen Matrix, Inc., and TELA Bio, Inc., and on the Board of CURE, Connecticut’s bioscience cluster, as well as the State of Connecticut’s Regenerative Medicine Advisory Committee. He has previously served as a Board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.

Larry Weiss is the General Counsel of Covidien’s Surgical Solutions global business unit.

Before joining Covidien’s predecessor company, Tyco Healthcare, Larry worked as an associate in the Corporate Department of Goodwin Procter, concentrating on corporate transactions, securities offerings and compliance. In 1999, Larry joined Tyco Healthcare, supporting the company on a variety of corporate, transactional and compliance matters including developing training programs addressing antitrust law, compliance with the US fraud and abuse regulations and the implementation of an International Trade compliance program.

In 2006, Larry was named Vice President and Chief International Officer, in anticipation of Tyco Healthcare’s separation from Tyco and created the company’s first dedicated international staff. In 2007, Tyco Healthcare was spun off from Tyco and renamed Covidien. Beginning in 2010, Larry also managed Covidien’s international IP staff in Switzerland and Japan.

In 2011, Larry was named the Vice President and General Counsel of Covidien Surgical Solutions, a newly formed business unit which combined Covidien’s surgical and energy-based devices businesses into the largest business unit of the company.

Covidien has worldwide sales of medical devices, supplies and pharmaceutical products of approximately $10.4 billion in over 140 countries and employs over 42,000 employees in 60 countries.

Andrew Zehner serves as Associate Vice President for Research, Technology Commercialization and Industry Relations at the University of Connecticut. He also serves in the Office of the General Counsel as Counsel for business transactions. Andrew has twenty years of experience providing strategic and business counsel to a wide variety of industries, including life sciences, health care, telecommunications, and information technology. Andrew was most recently Senior Corporate Counsel in the Legal Division of Pfizer Inc., supporting all aspects of pharmaceutical R&D in the U.S. and United Kingdom. He led the negotiations on many research, development and commercialization transactions. Prior to that, he served as counsel for Paradigm4, People’s Choice TV and HSS, Inc., all fast-growing Connecticut technology companies.

Zehner received a B.A. degree in American civilization from Middlebury College, an M.A. degree in history from the University of Massachusetts, Amherst, and a Juris Doctor with Honors from the University of Maryland School of Law. He is admitted to practice law in Connecticut and Maryland.

Serial Entrepreneur: David Scheer

Biotech Entrepreneur Kevin Rakin:
The Business of Science

A CT Bioscience Entrepreneur’s
Story: Craig M. Crews, Ph.D.


Talent Wanted/Talent Available

> Connecticut BioScience Job Listings
> BioScience Résumés

Click Here

Bioscience ClubhouseCT and Career Ladder Grant

Applications now being accepted. Get the details.
Click Here